Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05698888
Other study ID # VP301-001
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 29, 2022
Est. completion date June 19, 2023

Study information

Verified date September 2023
Source Virtuoso BINco, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.


Description:

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors. This study will be conducted in two parts: Dose Escalation - This part will evaluate increasing doses of VP301 to identify the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D). The first patient enrolled on the study will receive the lowest dose of VP301. Once this dose is shown to be safe, an additional patient will be enrolled at the next higher dose. Patients will continue to be enrolled into either single or multiple patient groups receiving increasing doses until the MTD or RP2D is reached. Dose Expansion - Patients with relapsed myeloma and lymphoma will be enrolled and treated with VP301 at the MTD or RP2D.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date June 19, 2023
Est. primary completion date June 19, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease - Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated. - Adequate kidney, liver, and hematologic function - Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 Exclusion Criteria: - Active brain metastases and history of leptomeningeal metastases. - Myeloma patients with plasmacytoma as only measurable disease - Non-secretory myeloma - Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications - Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) - Abnormal ECG - Has clinically significant cardiovascular disease - Additional active malignancy that may confound the assessment of the study endpoints - Pregnancy or lactation - Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C

Study Design


Intervention

Drug:
VP301
VP301 is an afucosylated humanized Fc-modified immunoglobulin G1 (IgG1) bispecific antibody targeting CD38 and ICAM-1.

Locations

Country Name City State
United States NEXT Oncology San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Virtuoso BINco, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Tumor expression Evaluate ICAM-1 and CD38 expression with clinical outcomes through study completion, an average of 30 months
Other Immunoglobulins Evaluate quantitative immunoglobulins with clinical outcomes through study completion, an average of 30 months
Primary Occurrence of General Toxicity Incidence of treatment-emergent serious AEs including toxicity and change from baseline in safety parameters through study completion, an average of 30 months
Primary Occurrence of Dose Limiting Toxicity Incidence of dose limiting toxicity during cycle 1 of dose escalation Over the first 21 days of VP301 dosing
Secondary Serum concentrations of VP301 Change from baseline in serum levels through study completion, an average of 30 months
Secondary Antidrug and neutralizing antibodies Change from baseline in serum levels through study completion, an average of 30 months
Secondary Objective response Assessed by IMWG for multiple myeloma, the Lugano criteria for lymphoma or RECIST 1.1 for solid tumors through study completion, an average of 30 months
Secondary Best response Assessed by IMWG for multiple myeloma, the Lugano criteria for lymphoma or RECIST 1.1 for solid tumors through study completion, an average of 30 months
Secondary Time to response and duration of response Assessed by IMWG for multiple myeloma or the Lugano criteria for lymphoma through study completion, an average of 30 months
Secondary Progression-free survival Assessed by IMWG for multiple myeloma or the Lugano criteria for lymphoma through study completion, an average of 30 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1